Bringing the fundamentals into focus…
Back to Akebia Therapeutics, Inc.
How Akebia Therapeutics, Inc. stacks up
AKBA · against 240 other Healthcare companies of similar size
Profitability
29/ 100
Below the middle of the pack.
Ranked #134 of 241 · scores higher than 44% of peers
Bars: peers in each 10-point band of the profitability score30 peers with a profitability score of 20–29, including AKBA · Click a bar to see the companies
Why profitability scores 29?
Weighted metrics compared with all Healthcare companies.Mainly because of its return on invested capital, return on assets and operating margin, which are weaker than most Healthcare peers.
- a lower return on invested capital: weaker than 76% of peers. Return on invested capital: -13.7% vs peer median 4.7%
- a lower return on assets: weaker than 74% of peers. Return on assets: -8.5% vs peer median 1.7%
- a thinner operating margin: weaker than 72% of peers. Operating margin: -6.9% vs peer median 7.1%
Metric by metric
Position: dot = AKBA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | AKBA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 200 reported | -13.7% | -2.4% | 39% | 33% | |
| Operating marginHigher is better · 221 reported | -6.9% | 0.4% | 43% | 33% | |
| Return on assetsHigher is better · 245 reported | -8.5% | -2.2% | 40% | 33% | |
| Return on equityHigher is better · 227 reported | -109.4% | -5.8% | 8% | Context only | |
| Gross marginHigher is better · 258 reported | 81.4% | 38.9% | 86% | Context only |
Ranking by profitability score
Top 5 and the companies ranked around AKBA| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 261M USD | 98 | 97 | |
| 2 | 1.4B HKD (≈$181M) | 97 | 61 | |
| 2 | 356M AUD (≈$235M) | 97 | 81 | |
| 4 | 592M ILS (≈$160M) | 96 | 84 | |
| 5 | 301M USD | 95 | 67 | |
| 129 | 2.4B HKD (≈$310M) | 30 | 52 | |
| 129 | 327M USD | 30 | 40 | |
| 129 | 354M USD | 30 | 41 | |
| 134 | 1.6B HKD (≈$209M) | 29 | 44 | |
| 134 | 201M USD | 29 | 24 | |
| 136 | 2.7B CNY (≈$383M) | 28 | 24 | |
| 136 | 172.4B KRW (≈$124M) | 28 | 26 | |
| 136 | 221M USD | 28 | 33 | |
| 136 | 223M USD | 28 | 34 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score